S7070 |
GSK J4 HCl
|
GSK J4 HCl是一种细胞渗透性的GSK J1前体药物,是第一个选择性H3K27组蛋白去甲基化酶JMJD3和UTX抑制剂,无细胞试验中IC50为60 nM,抑制JMJ家族的去甲基化酶活性。 |
-
Nat Cell Biol, 2024, 26(7):1165-1175
-
J Clin Invest, 2024, 134(24)e173403
-
J Clin Invest, 2024, 134(1)e163964
|
|
S8287 |
CPI-455 HCl
|
CPI-455 HCl 是特异性KDM5抑制剂,抑制全长KDM5A的IC50值为10 nM。在多种癌细胞系的治疗中,结合标准化疗或者靶向制剂,CPI-455能提高H3K4三甲基化(H3K4me3)整体水平,并减少DTPs的数量。 |
-
Nature, 2023, 622(7983):619-626
-
Nature, 2023, 622(7983):619-626
-
Cancer Cell, 2023, 41(6):1118-1133.e12
|
|
S7281 |
JIB-04
|
JIB-04 (NSC 693627)是一种广谱的选择性Jumonji histone demethylase抑制剂,无细胞试验中对JARID1A,JMJD2E,JMJD3,JMJD2A,JMJD2B,JMJD2C和JMJD2D的IC50分别是230 nM,340 nM,855 nM,445 nM,435 nM,1100 nM和290 nM。JIB‑04还可诱导细胞凋亡。 |
-
Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
-
Cancer Cell, 2023, 41(6):1118-1133.e12
-
mBio, 2022, 13(1):e0337721
|
|
S7296 |
ML324
|
ML324是一种选择性的jumonji histone demethylase (JMJD2)抑制剂, 其对JMJD2E的IC50为920 nM。
|
-
Cancer Cell, 2023, 41(6):1118-1133.e12
-
EBioMedicine, 2023, 92:104602
-
Viruses, 2023, 15(1)163
|
|
S7234 |
IOX1
|
IOX1 是2OG oxygenases强效的广谱抑制剂, 包括JmjC demethylases。 IOX1还是ALKBH5的抑制剂。 |
-
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
-
Front Immunol, 2024, 15:1308978
-
Cell Biol Toxicol, 2024, 40(1):99
|
|
S7581 |
GSK J1
|
GSK-J1是一种高效的 H3K27 histone demethylase JMJD3 (KDM6B) and UTX (KDM6A)的抑制剂,无细胞试验中对JMJD3 (KDM6B) 的 IC50 为 60 nM,比作用于其他测试的脱甲基酶选择性高10倍多,对JARID1B/C的 IC50 分别为0.95μM and 1.76μM。
|
-
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
-
Cell Rep Med, 2023, 4(5):101026
-
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
|
|
S8601 |
CP2
|
CP2是一种环肽,能够抑制JmjC histone demethylases KDM4,对KDM4A和KDM4C的IC50分别为42 nM和29 nM。 |
-
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
-
Oxid Med Cell Longev, 2022, 2022:2405943
-
Front Cell Dev Biol, 2021, 9:697614
|
|
E1315 |
iJMJD6
|
iJMJD6(WL12)是精氨酸去甲基酶JMJD6的抑制剂,IC50为0.22 μM。 |
|
|
F1232New |
JARID2 Rabbit mAb
|
JARID2,Jumonji/JARID2 |
|
|
S0201 |
Z-JIB-04 (NSC 693627)
|
Z-JIB-04 (NSC 693627, JIB-04 Z-isomer)是JIB-04的异构体。JIB-04 是一种泛选择性的 Jumonji histone demethylase 抑制剂,对于JARID1A、JMJD2E、JMJD3、JMJD2A、JMJD2B、JMJD2C和JMJD2D的IC50值分别为230 nM、340 nM、855 nM、445 nM、435 nM、1100 nM和290 nM。 |
|
|
S4800New |
Daminozide
|
Daminozide (Aminozide, DMASA, DIMG, B 995, Alar,Kylar,B-NINE, SADH), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily with IC50 of 1.5±0.7 μM for KDM2A. It is at least 100-fold selective as an inhibitor of the KDM2/7 subfamily over the other demethylase subfamily members tested, with IC50s of 2 μM or less against KDM2A, PHF8, and KIAA1718 and IC50s of 127 μM for KDM3A or greater (mM range) against other demethylases. |
|
|
S7070 |
GSK J4 HCl
|
GSK J4 HCl是一种细胞渗透性的GSK J1前体药物,是第一个选择性H3K27组蛋白去甲基化酶JMJD3和UTX抑制剂,无细胞试验中IC50为60 nM,抑制JMJ家族的去甲基化酶活性。 |
- Nat Cell Biol, 2024, 26(7):1165-1175
- J Clin Invest, 2024, 134(24)e173403
- J Clin Invest, 2024, 134(1)e163964
|
|
S8287 |
CPI-455 HCl
|
CPI-455 HCl 是特异性KDM5抑制剂,抑制全长KDM5A的IC50值为10 nM。在多种癌细胞系的治疗中,结合标准化疗或者靶向制剂,CPI-455能提高H3K4三甲基化(H3K4me3)整体水平,并减少DTPs的数量。 |
- Nature, 2023, 622(7983):619-626
- Nature, 2023, 622(7983):619-626
- Cancer Cell, 2023, 41(6):1118-1133.e12
|
|
S7281 |
JIB-04
|
JIB-04 (NSC 693627)是一种广谱的选择性Jumonji histone demethylase抑制剂,无细胞试验中对JARID1A,JMJD2E,JMJD3,JMJD2A,JMJD2B,JMJD2C和JMJD2D的IC50分别是230 nM,340 nM,855 nM,445 nM,435 nM,1100 nM和290 nM。JIB‑04还可诱导细胞凋亡。 |
- Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
- Cancer Cell, 2023, 41(6):1118-1133.e12
- mBio, 2022, 13(1):e0337721
|
|
S7296 |
ML324
|
ML324是一种选择性的jumonji histone demethylase (JMJD2)抑制剂, 其对JMJD2E的IC50为920 nM。
|
- Cancer Cell, 2023, 41(6):1118-1133.e12
- EBioMedicine, 2023, 92:104602
- Viruses, 2023, 15(1)163
|
|
S7234 |
IOX1
|
IOX1 是2OG oxygenases强效的广谱抑制剂, 包括JmjC demethylases。 IOX1还是ALKBH5的抑制剂。 |
- Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
- Front Immunol, 2024, 15:1308978
- Cell Biol Toxicol, 2024, 40(1):99
|
|
S7581 |
GSK J1
|
GSK-J1是一种高效的 H3K27 histone demethylase JMJD3 (KDM6B) and UTX (KDM6A)的抑制剂,无细胞试验中对JMJD3 (KDM6B) 的 IC50 为 60 nM,比作用于其他测试的脱甲基酶选择性高10倍多,对JARID1B/C的 IC50 分别为0.95μM and 1.76μM。
|
- Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
- Cell Rep Med, 2023, 4(5):101026
- Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
|
|
S8601 |
CP2
|
CP2是一种环肽,能够抑制JmjC histone demethylases KDM4,对KDM4A和KDM4C的IC50分别为42 nM和29 nM。 |
- Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
- Oxid Med Cell Longev, 2022, 2022:2405943
- Front Cell Dev Biol, 2021, 9:697614
|
|
E1315 |
iJMJD6
|
iJMJD6(WL12)是精氨酸去甲基酶JMJD6的抑制剂,IC50为0.22 μM。 |
|
|
S0201 |
Z-JIB-04 (NSC 693627)
|
Z-JIB-04 (NSC 693627, JIB-04 Z-isomer)是JIB-04的异构体。JIB-04 是一种泛选择性的 Jumonji histone demethylase 抑制剂,对于JARID1A、JMJD2E、JMJD3、JMJD2A、JMJD2B、JMJD2C和JMJD2D的IC50值分别为230 nM、340 nM、855 nM、445 nM、435 nM、1100 nM和290 nM。 |
|
|
S4800New |
Daminozide
|
Daminozide (Aminozide, DMASA, DIMG, B 995, Alar,Kylar,B-NINE, SADH), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily with IC50 of 1.5±0.7 μM for KDM2A. It is at least 100-fold selective as an inhibitor of the KDM2/7 subfamily over the other demethylase subfamily members tested, with IC50s of 2 μM or less against KDM2A, PHF8, and KIAA1718 and IC50s of 127 μM for KDM3A or greater (mM range) against other demethylases. |
|
|